CN1864722A - A pharmaceutical composition for treating muscles and bones pain and lumbar intervertebral disc protrusion - Google Patents
A pharmaceutical composition for treating muscles and bones pain and lumbar intervertebral disc protrusion Download PDFInfo
- Publication number
- CN1864722A CN1864722A CNA200510070868XA CN200510070868A CN1864722A CN 1864722 A CN1864722 A CN 1864722A CN A200510070868X A CNA200510070868X A CN A200510070868XA CN 200510070868 A CN200510070868 A CN 200510070868A CN 1864722 A CN1864722 A CN 1864722A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- herba
- pharmaceutical composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating waist disc protrusion, which is prepared from Chinese mugwort leafmulberry leaf, asaryl, secretio bufonis, sal-ammoniac, black catechu, wood louse, campeachy wood, eupatene, native copper, homalomena rhizoma, pangolin scales and Chinese ephedra.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of bones and muscles pain and prolapse of lumbar intervertebral disc.
Background technology
Prolapse of lumbar intervertebral disc belongs to motherland's medical science " lumbago and skelalgia " category, the traditional Chinese medical science is thought the dual function that having of this disease is inside and outside, endogenous cause of ill is meant the hypertrophy along with the age, kidney qi is gradually empty, waist QI and blood muscle arteries and veins bone marrow loses supports, and makes lumbar intervertebral disc degeneration gradually, specifically refers to constitute the cartilaginous lamina attenuation of lumbar intervertebral disc, fibrous ring elasticity weakens, and the vertebral pulp water content reduces; Exopathogenic factor is meant wound strain and wind-cold damp pathogen invasion, causes local qi depression to blood stasis, stagnation of QI and blood may bring about pain.Modern medicine is thought bulging, the compressing of vertebral pulp, cause inflammation, hyperemia, the edema of surrounding tissue, thereby pressuring neural root is the one of the main reasons that causes lumbago and skelalgia.Prolapse of lumbar intervertebral disc is again a commonly encountered diseases clinically, be mainly in the young and the middle aged, primary disease system causes that with reasons such as lumbar intervertebral disc generation degeneration and wounds fibrous ring partly or entirely destroys, together with vertebral pulp outwards bulging in the lump, pressuring neural root or spinal cord, a series of clinical symptoms that cause do not have some western medicines in treatment prolapse of lumbar intervertebral disc at present, but effect is not remarkable, and easily recurrence.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition that treatment bones and muscles pain and prolapse of lumbar intervertebral disc is had remarkable result.
The present invention is achieved through the following technical solutions: choose crude drug
Folium Artemisiae Argyi 1-3 weight portion Herba Asari 5-15 weight portion Venenum Bufonis 1-3 weight portion
Purple Sal Ammoniacus 1-3 weight portion Catechu 1-3 weight portion Eupolyphaga Seu Steleophaga 1.5-4.5 weight portion
Lignum Sappan 1-3 weight portion Herba Lycopi 1.5-4.5 weight portion Pyritum 0.5-1.5 weight portion
Rhizoma Homalomenae 1-3 weight portion Squama Manis 0.5-1.5 weight portion Herba Ephedrae 1.5-4.5 weight portion
Present composition optimum ratio is: choose crude drug
Folium Artemisiae Argyi 2 weight portion Herba Asaris 10 weight portion Venenum Bufoniss 2 weight portions
Purple Sal Ammoniacus 2 weight portion Catechu 2 weight portion Eupolyphaga Seu Steleophagas 3 weight portions
Lignum Sappan 2 weight portion Herba Lycopi 3 weight portion Pyritums 1 weight portion
Rhizoma Homalomenae 2 weight portion Squama Maniss 1 weight portion Herba Ephedrae 3 weight portions
The conventional adjuvant that pharmaceutical composition of the present invention adds is pharmaceutically made clinical acceptable forms, as in tablet, suppository, capsule, powder, granule, spray, ointment, emplastrum or the ointment any.
The present composition has blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, the effect of expelling wind and removing dampness, removing obstruction in the collateral to relieve pain; Remarkable to treatment bones and muscles pain and prolapse of lumbar intervertebral disc effect.
Following experimental example is used to further specify the present invention:
The patient who is diagnosed as prolapse of lumbar intervertebral disc that the present invention accepted for medical treatment outpatient service and ward from year June in June, 2002-2003, utilization the present invention " iliacus applies health bitterly " treatment obtains satisfactory effect, now is summarized as follows.
1, clinical data
1.1 among the physical data 80 routine patients, male 56 examples, women 24 examples: 25 years old-75 years old age; The course of disease did not wait in 1 month-10 years; 28 examples of companion's hyperosteogeny, 10 examples of companion's spinal canal stenosis.
1.2 diagnostic criteria is with reference to formulating about the diagnostic criteria of prolapse of lumbar intervertebral disc in " traditional Chinese medical science disease diagnosis criterion of therapeutical effect ", all case all has typical long-term chronic back pain history, the companion begins to lower limb radiating pain or numbness from buttocks, scoliosis, the waist physiologic radian disappears, the straight-leg raising test positive.All case is all done the lumbar vertebra CT examination, shows: prolapse of lumbar intervertebral disc.
2, Therapeutic Method
2.1 medicine is formed Folium Artemisiae Argyi 2kg, Herba Asari 10kg, Venenum Bufonis 2kg, purple Sal Ammoniacus 2kg, Catechu 2kg, Eupolyphaga Seu Steleophaga 3kg, Lignum Sappan 2kg, Herba Lycopi 3kg, Pyritum 1kg, Rhizoma Homalomenae 2kg, Squama Manis 1kg, Herba Ephedrae 3kg.
2.2 manufacture method: with said medicine routinely technology pulverize altogether, cross 80 mesh sieves.
2.3 the specification pack, every bag 40 gram.
2.4 every bag of medicine of usage adds 5 milliliters of edible distillate spirits earlier, reusable heat boiled water furnishing thick paste spreads on painful area, and is asymptomatic no matter lumbar vertebra has, and equally in the lumbar vertebra drug of topical application, each drug of topical application time is two hours, every the drug of topical application in three days once, and three next courses of treatment.
2.5 all dermatosiss of contraindication, anemia of pregnant woman's abdominal part and lumbosacral region are all forbidden after drinking.
3, criterion of therapeutical effect is with reference to formulating about the criterion of therapeutical effect of prolapse of lumbar intervertebral disc in " traditional Chinese medical science disease diagnosis criterion of therapeutical effect ".
Clinical recovery: the complete obiteration of lumbago and skelalgia symptom, upright walking freely, have a medical check-up: straight-leg raising test 70 degree, feminine gender can be recovered former work; Take a turn for the better: the lumbago and skelalgia sx, the waist movable function improves; Heal in the end: symptom and sign does not have improvement, straight-leg raising test 30 degree, the positive.
4, therapeutic outcome
Treat clinical recovery 36 examples after 2 courses of treatment, recovery from illness 50 examples after 3 courses of treatment, 26 examples that take a turn for the better, invalid 4 examples.Total effective rate 95%.
5, model case
Case 1: chapter * *, woman, 37 years old.Surplus May because of the right lower extremity moving obstacle, seek medical advice in August, 2002.
Disease is seen: right lower extremity aches the carbuncle discomfort, and pain is radiated to the right leg outside from RG, and companion's Ambulatory Activity is limited, need lean on and turn walking.Fear of cold, skelalgia are met cold increasing the weight of, and De Rezeshu haves a medical check-up: right lower extremity straight-leg raising test 20 (+), MRI are checked and are shown: L
4-5Intervertebral disk hernia, the fourth lumbar vertebra slippage.Diagnosis: 1. L
4-5Intervertebral disk hernia; 2. fourth lumbar vertebra slippage, with the back skelalgia complete obiteration of 3 week of said method treatment, walking is as ordinary person.Have a medical check-up: right lower extremity straight-leg raising test 85 (), strengthen test 60 (), follow up a case by regular visits to in February, 2005 the pain end send out again.
Case 2: open * *, the man, 50 years old, on October 15th, 2002 examined.Private prosecution: waist and right lower extremity pain, numbness 1 year, increase the weight of the companion and walked lamely 25 days.Waist and lower limb pain occurred before 1 year under not clear inducement, to outer court's diagnosis and treatment, bad during the symptom fashion, cause was had a cold in 25 days, and pain increases the weight of, and the companion walks lamely.Check: the lumbar vertebra normal physiological bending exists, no lateral bending, and waist 5 spinous process side is opened 2 centimeters tenderness and is radiated to right lower extremity, 15 ° in straight-leg raising test left side, the positive, it is positive to strengthen test, very the abdomen test is positive, the neck sign positive, numb outside the right thigh outside, the shank outside, the right foot, hypopselaphesia, Achilles tendon reflex weakens, muscular strength is normal, and the CT examination prompting: L～S intervertebral disc goes out root compression to right back lateral process.Be diagnosed as prolapse of lumbar intervertebral disc.With this law after 12 days patient's pain disappear substantially, the straight-leg raising test feminine gender, it is negative to strengthen test, very the abdomen test is negative, neck sign feminine gender, but left lower extremity still has a little numbness.Continue treatment after 1 month, all diseases all disappear, and walking freely.With examining 1 year, there is not recurrence.
Following embodiment is used to further specify the present invention:
Embodiment 1:
Folium Artemisiae Argyi 2kg Herba Asari 10kg Venenum Bufonis 2kg
Purple Sal Ammoniacus 2kg Catechu 2kg Eupolyphaga Seu Steleophaga 3kg
Lignum Sappan 2kg Herba Lycopi 3kg Pyritum 1kg
Rhizoma Homalomenae 2kg Squama Manis 1kg Herba Ephedrae 3kg
With said medicine routinely technology pulverize altogether, cross 80 mesh sieves and make powder, every bag 40 gram.Every bag of medicine adds 5 milliliters of edible distillate spirits earlier, and reusable heat boiled water furnishing thick paste spreads on painful area, and is asymptomatic no matter lumbar vertebra has, and equally in the lumbar vertebra drug of topical application, each drug of topical application time is two hours, every the drug of topical application in three days once, and three next courses of treatment.
Embodiment 2:
Folium Artemisiae Argyi 1kg Herba Asari 15kg Venenum Bufonis 1kg
Purple Sal Ammoniacus 3kg Catechu 1kg Eupolyphaga Seu Steleophaga 4.5kg
Lignum Sappan 1kg Herba Lycopi 4.5kg Pyritum 0.5kg
Rhizoma Homalomenae 3kg Squama Manis 0.5kg Herba Ephedrae 4.5kg
Said medicine technology is routinely made capsule.
Embodiment 3:
Folium Artemisiae Argyi 3kg Herba Asari 5kg Venenum Bufonis 3kg
Purple Sal Ammoniacus 1kg Catechu 3kg Eupolyphaga Seu Steleophaga 1.5kg
Lignum Sappan 3kg Herba Lycopi 1.5kg Pyritum 1.5kg
Rhizoma Homalomenae 1kg Squama Manis 1.5kg Herba Ephedrae 1.5kg
Said medicine technology is routinely made tablet.
Claims (8)
1, a kind of pharmaceutical composition for the treatment of bones and muscles pain and prolapse of lumbar intervertebral disc is characterized in that said composition is to be made by following crude drug:
Folium Artemisiae Argyi 1-3 weight portion Herba Asari 5-15 weight portion Venenum Bufonis 1-3 weight portion
Purple Sal Ammoniacus 1-3 weight portion Catechu 1-3 weight portion Eupolyphaga Seu Steleophaga 1.5-4.5 weight portion
Lignum Sappan 1-3 weight portion Herba Lycopi 1.5-4.5 weight portion Pyritum 0.5-1.5 weight portion
Rhizoma Homalomenae 1-3 weight portion Squama Manis 0.5-1.5 weight portion Herba Ephedrae 1.5-4.5 weight portion.
2, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
Folium Artemisiae Argyi 2 weight portion Herba Asaris 10 weight portion Venenum Bufoniss 2 weight portions
Purple Sal Ammoniacus 2 weight portion Catechu 2 weight portion Eupolyphaga Seu Steleophagas 3 weight portions
Lignum Sappan 2 weight portion Herba Lycopi 3 weight portion Pyritums 1 weight portion
Rhizoma Homalomenae 2 weight portion Squama Maniss 1 weight portion Herba Ephedrae 3 weight portions.
3, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
Folium Artemisiae Argyi 1 weight portion Herba Asari 15 weight portion Venenum Bufoniss 1 weight portion
Purple Sal Ammoniacus 3 weight portion Catechu 1 weight portion Eupolyphaga Seu Steleophaga 4.5 weight portions
Lignum Sappan 1 weight portion Herba Lycopi 4.5 weight portion Pyritums 0.5 weight portion
Rhizoma Homalomenae 3 weight portion Squama Maniss 0.5 weight portion Herba Ephedrae 4.5 weight portions.
4, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
Folium Artemisiae Argyi 3 weight portion Herba Asaris 5 weight portion Venenum Bufoniss 3 weight portions
Purple Sal Ammoniacus 1 weight portion Catechu 3 weight portion Eupolyphaga Seu Steleophagas 1.5 weight portions
Lignum Sappan 3 weight portion Herba Lycopi 1.5 weight portion Pyritums 1.5 weight portions
Rhizoma Homalomenae 1 weight portion Squama Manis 1.5 weight portion Herba Ephedraes 1.5 weight portions.
5,, it is characterized in that the conventional adjuvant that said composition adds pharmaceutically makes the dosage form of clinical acceptance according to claim 1,2,3 or 4 described pharmaceutical compositions.
6,, it is characterized in that the application of said composition in the medicine of preparation treatment bones and muscles pain according to claim 1,2,3 or 4 described pharmaceutical compositions.
7,, it is characterized in that the application of said composition in the medicine of preparation treatment prolapse of lumbar intervertebral disc according to claim 1,2,3 or 4 described pharmaceutical compositions.
8, pharmaceutical composition according to claim 5 is characterized in that described dosage form is: tablet, suppository, capsule, powder, granule, spray, ointment, emplastrum or ointment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200510070868XA CN1864722A (en) | 2005-05-20 | 2005-05-20 | A pharmaceutical composition for treating muscles and bones pain and lumbar intervertebral disc protrusion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200510070868XA CN1864722A (en) | 2005-05-20 | 2005-05-20 | A pharmaceutical composition for treating muscles and bones pain and lumbar intervertebral disc protrusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1864722A true CN1864722A (en) | 2006-11-22 |
Family
ID=37423974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200510070868XA Pending CN1864722A (en) | 2005-05-20 | 2005-05-20 | A pharmaceutical composition for treating muscles and bones pain and lumbar intervertebral disc protrusion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1864722A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906267A (en) * | 2015-06-10 | 2015-09-16 | 孔令刚 | Traditional Chinese medicine for treating lumbosacral spinal cord pain |
| CN105687472A (en) * | 2016-03-21 | 2016-06-22 | 广州暨南生物医药研究开发基地有限公司 | Medicinal composition for treating lubar intervertebral disc protrusion and preparation method of medicinal composition |
-
2005
- 2005-05-20 CN CNA200510070868XA patent/CN1864722A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906267A (en) * | 2015-06-10 | 2015-09-16 | 孔令刚 | Traditional Chinese medicine for treating lumbosacral spinal cord pain |
| CN105687472A (en) * | 2016-03-21 | 2016-06-22 | 广州暨南生物医药研究开发基地有限公司 | Medicinal composition for treating lubar intervertebral disc protrusion and preparation method of medicinal composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1118285C (en) | Shubi plaster for treating arthralgia due to wind-cold-dampness | |
| CN1895549A (en) | Soothe tendons and activating-blood anodyne plaster | |
| CN101406590B (en) | Chinese medicinal composition for treating rheumatism osteonosus and preparation method | |
| CN102895460B (en) | Traditional Chinese medicine composition for fracture and soft tissue injury | |
| CN1864722A (en) | A pharmaceutical composition for treating muscles and bones pain and lumbar intervertebral disc protrusion | |
| CN1840053A (en) | Medicine for treating arthritis, hyperosteogeny and intervertebral disc protrusion and preparation process thereof | |
| CN114652674A (en) | Blood circulation promoting and pain relieving ointment and preparation method thereof | |
| CN1259065C (en) | Chinese medicinal preparation for quick bone fracture setting | |
| CN1219524C (en) | Medicine for treating femoral head necrosis and its prepn | |
| CN102319330B (en) | Traditional Chinese medicine cataplasma for treating hyperosteogeny and preparation method thereof | |
| CN105168315A (en) | Zijin blood-dissipating pill for treating soft tissue contusion and early fracture | |
| CN1857685A (en) | Medicine ointment for treating swelling and pain in waist and knees | |
| CN1177600C (en) | Chinese medicine compound preparation for treating cervical spondylosis, and preparing process thereof | |
| CN1297305C (en) | Chinese medicinal composition for warming and transforming stasis, dispersing swell and engendering bone | |
| CN1255155C (en) | Medicine for curing rheumatic and rheumatoid diseases and its preparing method | |
| CN1319559C (en) | Pharmaceutical composition for treating muscle and bone pain and preparation method thereof | |
| CN1256127C (en) | Chinese patent medicine for injury of muscle and joint and its preparation | |
| CN101361882B (en) | Chinese medicine formulation for treating rheumatic osteoarthropathy | |
| CN102178758A (en) | Medicament for treating peripheral nerve of diabetes | |
| CN1231237C (en) | Medicine for treating hyperosteogeny | |
| CN1839927A (en) | Chinese traditional medicine for treating orthopaedic diseases and its preparation process | |
| CN1174768C (en) | Chinese medicine plaster for external application for curing hyperosteogeny, cervical spondylopathy and prolapse of lumbar intervertebral disk and its preparation method | |
| CN1846767A (en) | Chinese medicine bolus for treating protrusion of lumbar intervertebral disc | |
| CN1261146C (en) | Plaster for treating hyperplasia of mammary glands | |
| CN1297289C (en) | Chinese medicinal composition for warming and transforming stasis, dispelling dampness and dispersing swell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |